{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:32:18Z","timestamp":1761395538351,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"crossref","award":["PHA610372S"],"award-info":[{"award-number":["PHA610372S"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13346-019-00662-x","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T15:02:45Z","timestamp":1564585365000},"page":"59-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models"],"prefix":"10.1007","volume":"10","author":[{"given":"Faisal","family":"Usman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongdee","family":"Nopparat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerapol","family":"Srichana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"662_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327\u201360.","journal-title":"Clin Infect Dis"},{"key":"662_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/00063198-200205000-00008","volume":"8","author":"I Oren","year":"2002","unstructured":"Oren I, Goldstein N. Invasive pulmonary aspergillosis. Curr Opin Pulm Med. 2002;8:195\u2013200.","journal-title":"Curr Opin Pulm Med"},{"key":"662_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919\u201334.","journal-title":"Drugs"},{"key":"662_CR4","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/jps.21179","volume":"97","author":"JJ Torrado","year":"2008","unstructured":"Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci. 2008;97:2405\u201325.","journal-title":"J Pharm Sci"},{"key":"662_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1592\/phco.19.4.306.30934","volume":"19","author":"D Slain","year":"1999","unstructured":"Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy. 1999;19:306\u201323.","journal-title":"Pharmacotherapy"},{"key":"662_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"TJ Walsh","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Study Group. N Engl J Med. 1999;340:764\u201371.","journal-title":"N Engl J Med"},{"key":"662_CR7","first-page":"5403","volume":"9","author":"X Tang","year":"2014","unstructured":"Tang X, Zhu H, Sun L, Hou W, Cai S, Zhang R, et al. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. Int J Nanomedicine. 2014;9:5403\u201313.","journal-title":"Int J Nanomedicine"},{"key":"662_CR8","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1164\/rccm.200504-613PP","volume":"172","author":"S Gelperina","year":"2005","unstructured":"Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487\u201390.","journal-title":"Am J Respir Crit Care Med"},{"key":"662_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2005.02.003","volume":"296","author":"S Vyas","year":"2005","unstructured":"Vyas S, Quraishi S, Gupta S, Jaganathan K. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm. 2005;296:12\u201325.","journal-title":"Int J Pharm"},{"key":"662_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.08.017","volume":"269","author":"S Vyas","year":"2004","unstructured":"Vyas S, Kannan M, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm. 2004;269:37\u201349.","journal-title":"Int J Pharm"},{"key":"662_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/jac\/34.6.1001","volume":"34","author":"SD Allen","year":"1994","unstructured":"Allen SD, Sorensen KN, Neial MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone\u00ae) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994;34:1001\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1128\/AAC.41.2.259","volume":"41","author":"CE Cicogna","year":"1997","unstructured":"Cicogna CE, White MH, Bernard EM, Ishimura T, Sun M, Tong WP, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1997;41:259\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1128\/AAC.42.7.1597","volume":"42","author":"T Koizumi","year":"1998","unstructured":"Koizumi T, Kubo K, Kaneki T, Hanaoka M, Hayano T, Miyahara T, et al. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother. 1998;42:1597\u2013600.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1021\/js9604218","volume":"86","author":"MP Lambros","year":"1997","unstructured":"Lambros MP, Bourne DWA, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci. 1997;86:1066\u20139.","journal-title":"J Pharm Sci"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jac\/48.1.89","volume":"48","author":"EJ Ruijgrok","year":"2001","unstructured":"Ruijgrok EJ. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother. 2001;48:89\u201395.","journal-title":"J Antimicrob Chemother"},{"key":"662_CR16","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1016\/j.xphs.2017.08.013","volume":"106","author":"F Usman","year":"2017","unstructured":"Usman F, Ul-Haq Z, Khalil R, Tinpun K, Srichana T. Pharmacologically safe nanomicelles of amphotericin B with lipids: nuclear magnetic resonance and molecular docking approach. J Pharm Sci. 2017;106:3574\u201382.","journal-title":"J Pharm Sci"},{"key":"662_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1208\/s12249-015-0406-x","volume":"17","author":"K Adhikari","year":"2016","unstructured":"Adhikari K, Buatong W, Thawithong E, Suwandecha T, Srichana T. Factors affecting enhanced permeation of amphotericin B across cell membranes and safety of formulation. AAPS PharmSciTech. 2016;17:820\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"662_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ijpharm.2014.05.066","volume":"471","author":"KN Gangadhar","year":"2014","unstructured":"Gangadhar KN, Adhikari K, Srichana T. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Int J Pharm. 2014;471:430\u20138.","journal-title":"Int J Pharm"},{"key":"662_CR19","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/bmc.3198","volume":"28","author":"BT Al-Quadeib","year":"2014","unstructured":"Al-Quadeib BT, Radwan MA, Siller L, Mutch E, Horrocks B, Wright M, et al. Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS\/MS assay: monitoring amphotericin B in patients using UPLC. Biomed Chromatogr. 2014;28:1652\u20139.","journal-title":"Biomed Chromatogr"},{"key":"662_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-3659(97)00245-9","volume":"53","author":"B Yu","year":"1998","unstructured":"Yu B, Okano T, Kataoka K, Kwon G. Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. J Control Release. 1998;53:131\u20136.","journal-title":"J Control Release"},{"key":"662_CR21","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1128\/AAC.41.5.886","volume":"41","author":"R Bhamra","year":"1997","unstructured":"Bhamra R, Sa\u2019ad A, Bolcsak LE, Janoff AS, Swenson CE. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother. 1997;41:886\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2006.08.013","volume":"329","author":"W Tiyaboonchai","year":"2007","unstructured":"Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B\u2013chitosan\u2013dextran sulfate nanoparticles. Int J Pharm. 2007;329:142\u20139.","journal-title":"Int J Pharm"},{"key":"662_CR23","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1128\/AAC.47.10.3339-3342.2003","volume":"47","author":"V Risovic","year":"2003","unstructured":"Risovic V, Boyd M, Choo E, Wasan KM. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother. 2003;47:3339\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejps.2009.02.021","volume":"37","author":"SH Jung","year":"2009","unstructured":"Jung SH, Lim DH, Jung SH, Lee JE, Jeong K-S, Seong H, et al. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci. 2009;37:313\u201320.","journal-title":"Eur J Pharm Sci"},{"key":"662_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1128\/AAC.35.4.615","volume":"35","author":"JM Clark","year":"1991","unstructured":"Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 1991;35:615\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR26","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/AAC.38.9.2224","volume":"38","author":"KM Wasan","year":"1994","unstructured":"Wasan KM, Grossie VB, Lopez-Berestein G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994;38:2224\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","volume":"26","author":"A Puri","year":"2009","unstructured":"Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523\u201380.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"662_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2015.01.015","volume":"70","author":"LR Caldeira","year":"2015","unstructured":"Caldeira LR, Fernandes FR, Costa DF, Fr\u00e9zard F, Afonso LCC, Ferreira LAM. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis. Eur J Pharm Sci. 2015;70:125\u201331.","journal-title":"Eur J Pharm Sci"},{"key":"662_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijpharm.2014.08.035","volume":"475","author":"M Zhao","year":"2014","unstructured":"Zhao M, Hu J, Zhang L, Zhang L, Sun Y, Ma N, et al. Study of amphotericin B magnetic liposomes for brain targeting. Int J Pharm. 2014;475:9\u201316.","journal-title":"Int J Pharm"},{"key":"662_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijpharm.2013.02.038","volume":"447","author":"DR Serrano","year":"2013","unstructured":"Serrano DR, Hern\u00e1ndez L, Fleire L, Gonz\u00e1lez-Alvarez I, Montoya A, Ballesteros MP, et al. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int J Pharm. 2013;447:38\u201346.","journal-title":"Int J Pharm"},{"key":"662_CR31","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","volume":"41","author":"DJ Diekema","year":"2003","unstructured":"Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623\u20136.","journal-title":"J Clin Microbiol"},{"key":"662_CR32","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1128\/AAC.05956-11","volume":"56","author":"V Salas","year":"2012","unstructured":"Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, et al. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob Agents Chemother. 2012;56:2246\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"662_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","volume":"49","author":"B Dupont","year":"2002","unstructured":"Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49:31\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"662_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1086\/513943","volume":"26","author":"DW Denning","year":"1998","unstructured":"Denning DW. Invasive Aspergillosis. Clin Infect Dis. 1998;26:781\u2013803.","journal-title":"Clin Infect Dis"},{"key":"662_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/thx.50.12.1321","volume":"50","author":"IF Purcell","year":"1995","unstructured":"Purcell IF, Corris PA. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax. 1995;50:1321\u20133.","journal-title":"Thorax."},{"key":"662_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1183\/09031936.95.08081263","volume":"8","author":"P Diot","year":"1995","unstructured":"Diot P, Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J. 1995;8:1263\u20138.","journal-title":"Eur Respir J"},{"key":"662_CR37","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1378\/chest.108.3.750","volume":"108","author":"J Dubois","year":"1995","unstructured":"Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest. 1995;108:750\u20133.","journal-title":"Chest."},{"key":"662_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00000421-199302000-00011","volume":"16","author":"J Gryn","year":"1993","unstructured":"Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol. 1993;16:43\u20136.","journal-title":"Am J Clin Oncol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-019-00662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-019-00662-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-019-00662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T23:37:07Z","timestamp":1596065827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-019-00662-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s13346-019-00662-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"type":"print","value":"2190-393X"},{"type":"electronic","value":"2190-3948"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"31 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Biodistribution and histopathology studies were performed that strictly followed the ethical guidelines approved by the animal ethics committee, Prince of Songkla University (MOE 0521.11\/522, Ref. 08\/2015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}